Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128303) titled 'Study of GS-5319 in Adults With Solid Tumors' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Gilead Sciences
Condition:
Advanced Solid Tumor
Intervention:
Drug: GS-5319
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 2025
Target Sample Size: 178
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07128303
Published by HT Digital Content Services with permission from Health Daily Digest....